Kaléo announced on May 7 the launch of a new Medical Affairs website designed to support healthcare professionals with resources focused on anaphylaxis, particularly in pediatric patients including infants and toddlers.
The company said the platform aims to help clinicians make informed decisions by providing access to disease education, clinical data, and emerging scientific insights. The site also offers information that can be shared with patients and caregivers, supporting preparedness and outcomes during allergic emergencies.
According to Kaléo, the Medical Affairs website serves as a centralized hub for clinical data on anaphylaxis, peer-reviewed publications, research presented at medical congresses, and real-world evidence related to its therapies and drug-device combination technologies such as the Aerio auto-injector platform. The company said this resource is intended to bridge the gap between clinical research and practical application in patient care.
Key features of the site include a Healthcare Professional Resource Center with evidence-based guidance for pediatric allergy management; access to scientific publications covering evolving treatment paradigms; and updates from medical congresses highlighting developments in drug-device technology for anaphylaxis treatment. “An important goal of the Kaléo Medical Affairs website is to translate complex clinical insights into practical, actionable information in support of HCPs efforts to assist their patients’ and caregivers’ preparedness and outcomes in allergic emergencies,” according to the company.
Kaléo stated that this initiative reflects its ongoing commitment to advancing scientific exchange among healthcare providers. The new Medical Affairs website can be accessed at www.kaleomedicalaffairs.com.